arrow
R

Robert Metcalf

University of Manchester
H指数:15
被引数:2,414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Seasonal variations in overall survival and vitamin D status in a UK pan-cancer cohort receiving checkpoint inhibitors

英国泛癌种队列接受免疫检查点抑制剂治疗患者的总体生存率及维生素D状态的季节性变化

2026-09-290
OAAI
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 study

皮下注射阿曼曲单抗在复发性/转移性头颈鳞状细胞癌中的应用:在免疫检查点抑制剂和化疗后疾病进展的患者中的初步结果,来自OrigAMI-4研究(1b/2期)

2025-11-220
OAAI
Evaluation of Clinical Parameters Associated with Response and Resistance to Cemiplimab in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma: A Multi-Institutional Retrospective Cohort Study

评估与cemiplimab应答和耐药性相关的临床参数:在局部晚期和转移性皮肤鳞状细胞癌中的多中心回顾性队列研究

2025-03-150
OA
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK

在英国使用pembrolizumab单药治疗头颈部鳞状细胞癌 (HNSCC)

2024-04-290
OA
Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer

HPV相关口咽癌 (化疗) 放疗后随访成像频率与时间发生率和远处失败模式的关系

2024-01-011
PRE
INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
2023-10-016
OA
ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
2021-09-015
OAAI
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer
CANCER
IF5.1
2020-06-1840
OAAI
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
2019-04-22203
OAAI